How does Keytruda (pembrolizumab) work in cancer?
Keytruda is an immunotherapy drug called a PD-1 (programmed death-1) inhibitor. It works by blocking the PD-1 pathway, which helps cancer cells avoid immune attack. By inhibiting PD-1, Keytruda restores and strengthens T-cell activity against tumor cells [1].
What does blocking PD-1 change in the immune system?
PD-1 is a checkpoint receptor on T cells. When PD-1 signals through its partners (including PD-L1 on tumor cells or other cells in the tumor environment), it can “turn down” T-cell responses. Keytruda prevents that inhibitory signaling by blocking PD-1, allowing T cells to stay active and better recognize and kill cancer cells [1].
Which patients and cancers use this mechanism?
Keytruda’s PD-1 blocking approach is used across multiple cancer types, including cases where tumors use the PD-1/PD-L1 pathway to evade the immune system. The specific indications depend on the cancer type and tumor biomarkers, but the underlying mechanism—releasing the brakes on T cells by blocking PD-1—stays the same [1].
Does Keytruda kill cancer directly?
No. Keytruda does not act as a direct cytotoxic chemotherapy agent. Its effect comes from modulating the immune response—specifically by reactivating T-cell anti-tumor activity through PD-1 blockade [1].
What does this mean for side effects patients ask about?
Because Keytruda boosts immune activity, it can cause immune-related side effects when the activated immune system affects normal tissues. This is consistent with the checkpoint-inhibitor mechanism of PD-1 blockade [1].
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/